Industry news that matters to you.  Learn more

Archives for September 2012

Brigham and Women’s Hospital Researchers Fnd that Missing Pieces of DNA Structure are a Red Flag for Deadly Skin Cancer

Melanoma is the most dangerous type of skin cancer and is the leading cause of death from skin disease. Rates are steadily increasing, and although risk increases with age, melanoma is now frequently seen in young people. But what if we could pinpoint when seemingly innocuous skin pigment cells mutate into melanoma? Researchers at Brigham and Women’s Hospital (BWH) have achieved this. Teams led by Yujiang Geno Shi, PhD, from BWH’s Department of Medicine, and George F. Murphy, MD, from BWH’s Department of Pathology have discovered a new biomarker for the lethal disease. The findings offer novel opportunities for skin cancer diagnostics, treatment and prevention.

Qiagen Teams with China’s Lepu Medical to Provide Rapid Diagnosis of Heart Attacks Using Point of Need Testing

Qiagen N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced an agreement with Lepu Medical Technology (Beijing) Co., Ltd., a leading medical device company in China, to provide Qiagen’s ESEQuant Lateral Flow System for use in emergency rooms with Lepu’s tests for cardiac markers that diagnose acute myocardial infarction (heart attack). The agreement expands Qiagen’s presence in China and adds a new point of need diagnostics application.

Research Study of Triple Negative Breast Cancer Highlights Ability of NextBio Clinical to Identify Biomarkers

The ability of NextBio Clinical to rapidly identify biomarkers and possible disease targets in an aggressive form of breast cancer was highlighted this week in a poster presentation at the American Society of Clinical Oncology’s 2012 Breast Cancer Symposium. NextBio Clinical was used to investigate a cohort of published patient data, curated by NextBio, for key differences between Triple Positive Breast Cancer (TPBC) and Triple Negative Breast Cancer (TNBC), a form of the disease that offers a worse prognosis for those diagnosed. Results of the study quickly identified several key differences in gene expression and methylation status between the two breast cancer types, as well as a novel biomarker and potential alternate way of treating TNBC.

GNS Healthcare, Covance Team on Data-Driven Personalized Medicine

GNS Healthcare today said that it will collaborate with contract research organization Covance on developing data-driven models to assist pharmaceutical firms in optimizing the efficiency and cost-effectiveness of drug development.

Trovagene, Inc., Grants License for NPM1 Marker to Quest Diagnostics for Acute Myelogenous Leukemia

Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, announced it has granted Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services related to acute myelogenous leukemia (AML). Trovagene holds an exclusive worldwide license to US patent 8,222,370 and the corresponding group of U.S. and foreign patent applications around NPM. Terms of the agreement include upfront fees and royalty payments on an annual basis. Additional terms were not disclosed.